Overview
PDS Biotech’s oncology pipeline leverages the Versamune® and Versamune® plus PDS0301 platform technologies in combination with proprietary tumor-specific proteins or peptides (antigens) in the development of targeted cancer immunotherapies.
| Products | Indication | Combination | PC | P1 | P2 | P3 | R | PARTNER(S) |
|---|---|---|---|---|---|---|---|---|
| Oncology | ||||||||
| PDS0101 (HPV16) Learn more |
VERSATILE-002 Recurrent/metastatic HPV16-positive head and neck cancer |
KEYTRUDA® (Standard of Care) |
|
|
 |
|||
| Arm 1: Checkpoint inhibitor naïve 1st line treatment | ||||||||
| Arm 2: Checkpoint inhibitor refractory 2nd or 3rd line treatment | ||||||||
| PDS0101 (HPV16) PDS0301 Learn more |
HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers | Bintrafusp alfa |
|
|
 |
|||
| Arm 1: Checkpoint inhibitor naïve 2nd line treatment | ||||||||
| Arm 2: Checkpoint inhibitor refractory 3rd line treatment | ||||||||
| PDS0101 (HPV16) Learn more |
IMMUNOCERV 1st line treatment of locally advanced (IB3-IVA) cervical cancer |
Chemo-radiation (Standard of Care) |
|
|
 |
|||
| PDS0101 (HPV16) Learn more |
Pre-metastatic HPV-associated oropharyngeal cancer (OPSCC) | KEYTRUDA® (Standard of Care) |
|
|
 |
|||
| Arm 1: PDS0101 monotherapy | ||||||||
| Arm 2: PDS0101 + KEYTRUDA | ||||||||
| PDS0102 (TARP) |
TARP-associated AML, prostate and breast cancers | TBD |
|
|
|
|||
| PDS0103 (MUC1) |
MUC1-associated breast, colon, lung, ovarian and other cancers | TBD |
|
|
|
|||
| PDS0104 (TRP2) |
Melanoma | TBD |
|
|
||||
PDS Biotech Funded  |
Partner Co-Funded  |
|||||||